PUBLISHER: BCC Research | PRODUCT CODE: 2140277
PUBLISHER: BCC Research | PRODUCT CODE: 2140277
The global market for latest developments, product innovations, and treatments for diabetes was valued at $144.5 billion in 2025 and is estimated to increase from $162.2 billion in 2026 to reach $295 billion by the end of 2031, at a compound annual growth rate (CAGR) of 12.7% from 2026 to 2031.
The report provides an overview of the global market for latest developments, product innovations, and treatments for diabetes. It includes global revenue ($ million) using 2025 as the base year, estimated data for 2026, and projected data for 2026 through 2031.
By product, the market is segmented into diabetic pharmaceuticals, glucose monitoring device technologies, and insulin delivery device technologies. Diabetic pharmaceuticals comprise injectable therapies and oral antidiabetic drugs (OADs). Glucose monitoring device technologies cover blood glucose test strips (BGTS), blood glucose meters, continuous glucose monitoring (CGM) systems, and lancets and lancet devices. Insulin delivery device technologies include insulin pens and needles, insulin pumps, and insulin syringes. By region, the market is segmented into North America (U.S., Canada, Mexico), Europe (Germany, the U.K., Italy, France, Spain, and the Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia-Pacific), the Middle East and Africa (MEA), and South America, focusing on all major countries within these regions.
This study focuses on the driving trends and challenges that affect the market and vendor landscape. It discusses emerging technologies related to the market.
The report concludes by analyzing the competitive landscape and providing leading companies in diabetes therapy, glucose monitoring devices, and insulin delivery devices in the market. It also contains a dedicated section of company profiles that covers company overviews, key financials, product portfolios, and recent developments.